NCT06343376 2025-08-03
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
Phase 1 Terminated
Clinical Trials
8 trialsNCT03103971 2024-04-10
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT03240861 2023-11-01
NYESO SCT
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT03121677 2023-08-14
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Washington University School of Medicine
Phase 1 Terminated
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT03126864 2019-11-04
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01902771 2017-03-10
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
University of Miami
Phase 1 Terminated
NCT01783431 2015-10-02
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
Medical University of South Carolina
Phase 1 Terminated